Genomic and Precision Medicine

Genomic and Precision Medicine

Oncology

3rd Edition - April 9, 2022

Write a review

  • Editors: Geoffrey Ginsburg, Huntington Willard, John Strickler, Matthew McKinney
  • Hardcover ISBN: 9780128006849
  • eBook ISBN: 9780128006535

Purchase options

Purchase options
Available
DRM-free (PDF, EPub)
Sales tax will be calculated at check-out

Institutional Subscription

Free Global Shipping
No minimum order

Description

Genomic and Precision Medicine: Oncology, Third Edition focuses on the applications of genome discovery as research points to personalized cancer therapies. Each chapter is organized to cover the application of genomics and personalized medicine tools and technologies to a) Risk Assessment and Susceptibility, b) Diagnosis and Prognosis, c) Pharmacogenomics and Precision Therapeutics, and d) Emerging and Future Opportunities in the field.

Key Features

  • Provides a comprehensive volume written and edited by oncology genomic specialists for oncology health providers
  • Includes succinct commentary and key learning points that will assist providers with their local needs for implementation of genomic and personalized medicine into practice
  • Presents an up-to-date overview on major opportunities for genomic and personalized medicine in practice
  • Covers case studies that highlight the practical use of genomics in the management of patients

Readership

Medical students, life sciences and engineering graduate students, advanced undergraduate students, and residents and fellows working with any aspect of genomic research in the life sciences and/or medicine; educators, and translational scientists

Table of Contents

  • Cover image
  • Title page
  • Table of Contents
  • Copyright
  • List of contributors
  • Preface
  • Chapter 1. Introduction and overview of cancer precision medicine
  • Abstract
  • Background
  • Opportunities and challenges in precision oncology
  • Summary
  • References
  • Chapter 2. From data to knowledge: an introduction to biomedical informatics
  • Abstract
  • Introduction
  • A primer on the role of biomedical informatics in the era of precision approaches to research, healthcare delivery, and population health
  • A framework for selecting, understanding, and assessing biomedical informatics methods
  • The relationship between problem solving and methods selection
  • Conclusion
  • Glossary and abbreviations
  • References
  • Chapter 3. The functional genome: epigenetics and epigenomics
  • Abstract
  • Introduction
  • The composition of the epigenome
  • Histone modifications
  • Epigenetic mechanisms of disease
  • Epigenetic responses to the environment
  • Heritability of the epigenome
  • Genome-wide observation of the epigenome
  • References
  • Chapter 4. Clinical decision support and molecular tumor boards
  • Abstract
  • Introduction
  • Assembling the right team
  • Patient and test selection
  • Generating clinical recommendations
  • Areas for improvement and concluding remarks
  • References
  • Chapter 5. Family health history and health risk assessment in oncology
  • Abstract
  • Introduction
  • In the beginning
  • Why family health history is central to HRAs
  • An implementation crisis
  • Will providers use it?
  • Will the patients use it?
  • What about patient-entered data?
  • Does it make a difference?
  • Conclusion
  • References
  • Chapter 6. Lymphomas: molecular subsets and advances in therapeutics
  • Abstract
  • Introduction
  • Diffuse large B-cell lymphoma
  • Follicular lymphoma
  • Burkitt lymphoma
  • Mantle cell lymphoma
  • Leveraging genomics for precision medicine in lymphoma clinical care
  • Summary
  • References
  • Chapter 7. Precision medicine in myeloid neoplasms/acute leukemias
  • Abstract
  • Introduction
  • Spectrum of disease(s)
  • Approach to prognosis and treatment recommendations in acute myeloid leukemia
  • Summary
  • References
  • Chapter 8. Lung cancer
  • Abstract
  • Introduction
  • Lung cancer risk and screening
  • Diagnosis and molecular characteristics
  • Early stage disease
  • Genetic testing in metastatic disease
  • EGFR mutations
  • Squamous cell carcinoma and small-cell lung cancer
  • Immunotherapy
  • Future directions
  • Metastatic disease
  • Conclusion
  • References
  • Chapter 9. Breast cancer
  • Abstract
  • Introduction
  • Estrogen receptor
  • Cyclin-dependent kinase, phosphatidylinositol 3-kinase, and mammalian target of rapamycin
  • HER2/neu
  • Poly(ADP-ribose) polymerase inhibitors
  • Immunotherapy
  • Conclusion
  • References
  • Chapter 10. Epithelial ovarian cancer
  • Abstract
  • Inherited syndromes
  • Histologic origins of ovarian cancer
  • Genetic hallmarks of ovarian cancer
  • Genetic events contributing to ovarian cancer metastasis
  • Role of immune responses
  • Angiogenesis
  • Summary
  • References
  • Chapter 11. Endometrial cancer
  • Abstract
  • The Bokhman classification of endometrial cancers
  • The Cancer Genome Atlas
  • The proactive molecular risk classifier for endometrial cancer (ProMisE) algorithm
  • Targetable alterations
  • References
  • Chapter 12. Colorectal cancer
  • Abstract
  • Introduction
  • Colorectal cancer genetics
  • Diagnosis and prognosis of colorectal cancer
  • Precision therapeutics for colorectal cancer
  • Novel and emerging therapeutics and future opportunities
  • Conclusions
  • Disclosures
  • References
  • Chapter 13. Hepatic and bile duct cancers
  • Abstract
  • Introduction
  • Epidemiology
  • Genomic alterations
  • Integrative molecular classification
  • Clinical applications of genomics
  • Conclusion
  • References
  • Chapter 14. Biomarker-directed therapy for pancreatic cancer
  • Abstract
  • Introduction
  • Pancreatic cancers harbor actionable mutations
  • FDA-approved, biomarker-based therapies for pancreatic cancer
  • Additional promising targets
  • Elusive drivers: KRAS, TP53, CDKN2A/2B, and SMAD4
  • Future considerations
  • Concluding remarks
  • References
  • Chapter 15. Esophageal and gastric cancer
  • Abstract
  • Introduction
  • Epidemiology and risk factors
  • Current classification
  • Molecularly targeted therapies in advanced disease
  • Immunotherapy in esophageal and gastric cancers
  • Key barriers to genomic medicine in esophageal and gastric cancers
  • Conclusion and future directions
  • References
  • Chapter 16. Prostate Cancer
  • Abstract
  • Introduction
  • Precision prostate cancer screening
  • Management of localized prostate cancer
  • Precision oncology advances in metastatic prostate cancer
  • Challenges
  • Conclusions
  • References
  • Chapter 17. Genomics and precision medicine: kidney cancer
  • Abstract
  • Introduction
  • Genomic and molecular profiling of renal cell carcinoma subtypes
  • Prognostic implications of molecular markers
  • Predictive biomarkers and targeted therapeutics
  • Conclusion
  • References
  • Chapter 18. Head and neck squamous cell carcinoma
  • Abstract
  • Predisposition
  • Screening
  • Diagnosis
  • Prognosis
  • Pharmacogenomics
  • Monitoring
  • Novel and emerging therapeutics
  • Surgery
  • Radiation therapy
  • Targeted therapies
  • Conclusion
  • References
  • Chapter 19. Melanoma
  • Abstract
  • Introduction
  • Melanoma progression
  • Genetics of melanoma
  • Clinical applications of genomics in melanoma
  • Conclusion
  • References
  • Chapter 20. Precision cancer immunotherapy
  • Abstract
  • Introduction
  • Immune effector cells, recognition of cancer cells as “foreign” and the cancer microenvironment
  • T-cell immunotherapy approaches in cancer
  • Prediction of response to immune checkpoint inhibitors and other immunotherapy agents
  • Summary
  • References
  • Index

Product details

  • No. of pages: 378
  • Language: English
  • Copyright: © Academic Press 2022
  • Published: April 9, 2022
  • Imprint: Academic Press
  • Hardcover ISBN: 9780128006849
  • eBook ISBN: 9780128006535

About the Editors

Geoffrey Ginsburg

Dr. Ginsburg is the founding Director of the Center for Applied Genomics & Precision Medicine in the Duke Institute for Genome Sciences & Policy. He is also Professor of Medicine and of Pathology at Duke University Medical Center, Professor of Biomedical Engineering at Duke Pratt School of Engineering, and Co-Director of the Duke Translational Medicine Institute.

Affiliations and Expertise

Chief Medical and Scientific Officer, All of Us Research Program, National Institutes of Health, Bethesda, Maryland, USA

Huntington Willard

Huntington Willard is on the faculty of the Department of Human Genetics at the University of Chicago. Prior to this appointment, Willard was the President and Director of the Marine Biological Laboratory and Professor of Human Genetics at the University of Chicago. He was previously on the faculty at Duke University, where he was founding director of the university-wide Duke Institute for Genome Sciences & Policy from 2003 to 2014, the Nanaline H. Duke Professor of Genome Sciences, and the Arts & Sciences Professor of Biology & Genome Sciences.

Affiliations and Expertise

Chief Scientific Officer, Genome Medical, Inc., South San Francisco, CA, USA

John Strickler

John Strickler is Associate Professor in the Department of Medicine, Division of Medical Oncology at Duke University Medical Center, Durham, NC, USA.

Affiliations and Expertise

Associate Professor, Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA

Matthew McKinney

Matthew Stuart McKinney is Assistant Professor of Medicine in the Department of Medicine, Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA.

Affiliations and Expertise

Assistant Professor of Medicine, Department of Medicine, Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA

Ratings and Reviews

Write a review

There are currently no reviews for "Genomic and Precision Medicine"